NX-13: Clinical Trials

3 trials of NX-13, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 2 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Completed 2
Phase 21Terminated 1

Follow NX-13: new trials by email Literature Review of NX-13 trials Research Report on NX-13

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
NX-13 250mg, NX-13 750mg, NX-13 Placebo - Ulcerative Colitis
Phase 2TerminatedAbbVie812023-04-242026-06-15
Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
NX-13 250mg IR, NX-13 500mg IR, NX-13 500mg MR - Ulcerative Colitis
Phase 1CompletedLandos Biopharma Inc.392021-05-052023-02-15
Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female Volunteers
NX-13 250 mg, Placebo - Ulcerative Colitis
Phase 1CompletedLandos Biopharma Inc.562020-07-102022-03-10

Conditions studied

Colitis, Ulcerative (3)  ·  Lymphoma, Follicular (1)

Sponsors

Landos Biopharma Inc. (2)  ·  AbbVie (1)

Countries

United States (2)  ·  Australia (1)  ·  Belgium (1)  ·  Italy (1)  ·  Poland (1)  ·  Ukraine (1)

Top investigators

Simon Lichtiger, MD (2)

Results publications

PMID 37952114